5 (507) In stock
Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
Volume 8, issue 1 Multidisciplinary Respiratory Medicine
PDF) Targeting G4 motifs of various stem cell makers with designed peptide for therapeutic applications
Cancers, Free Full-Text
Biomedicines, Free Full-Text
Cancers, Free Full-Text
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives, Biomarker Research
Frontiers Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression
CD38 as a PET Imaging Target in Lung Cancer
eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer
